Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like Filings Reveal Founder & CEO Buy Adds $570K to Retractable Tech Stake August 30, 2017 Novo Nordisk Lays Off 185 Employees, Hiring 70 in Commercial Reorg November 12, 2017 FDA Accepts GW Pharma's Epidiolex NDA With Priority Review for Lennox-Gastaut Syndrome and Dravet… December 27, 2017
FDA Accepts GW Pharma's Epidiolex NDA With Priority Review for Lennox-Gastaut Syndrome and Dravet… December 27, 2017
